1. Create broad-spectrum and specific targeted anticancer lead drugs of Bcl-2 family proteins, including inhibitors, agonists and PROTACTs molecules;

2. The confirmation and visualization of pan-Bcl-2 family tumor targets, including the confirmation of known multi-drug target combinations of Bcl-2 family, the discovery of new Bcl-2 family proteins and the study of tumor target significance.